Currently out of the existing stock ratings of Douglas Miehm, 19 are a HOLD (31.15%), 42 are a BUY (68.85%).

Douglas Miehm

Work Performance Price Targets & Ratings Chart

Analyst Douglas Miehm, currently employed at RBC, carries an average stock price target met ratio of 49.4% that have a potential upside of 27.33% achieved within 163 days. Previously, Douglas Miehm worked at CHINA RENAISSANCE.

Douglas Miehm’s has documented 122 price targets and ratings displayed on 6 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on LGND, Ligand Pharmaceuticals at 10-Dec-2025.

Wall Street Analyst Douglas Miehm

Analyst best performing recommendations are on AUPH (AURINIA PHARMACEUTICALS).
The best stock recommendation documented was for BHC (BAUSCH HEALTH COMPANIES) at 5/5/2023. The price target of $8 was fulfilled within 13 days with a profit of $2.17 (37.22%) receiving and performance score of 28.63.

Average potential price target upside

of $25.77 (24.53%) on LGND (LIGAND PHARMACEUTICALS).
of $5.23 (58.62%) on AUPH (AURINIA PHARMACEUTICALS).
of $3.2 (21.87%) on BLCO (BAUSCH + LOMB CORP).

AUPH Aurinia Pharmaceuticals BHC Bausch Health Companies BLCO Bausch + Lomb Corp LGND Ligand Pharmaceuticals MNKD MannKind Corp ONCY Oncolytics Biotech

Show more stocks

Analyst name

Rating

Rating initiation date

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score